Core Viewpoint - The article discusses the divestment of a 17.87% stake in Tianmai Biotechnology by China Resources Pharmaceutical, marking a significant shift in strategy after a decade of investment in oral insulin, which has faced multiple setbacks and challenges in commercialization [5][9]. Group 1: Company Background and Investment History - China Resources Pharmaceutical began its investment in Tianmai Biotechnology in 2016, focusing on the development and commercialization of insulin and its analogs, particularly oral insulin [5]. - The initial optimism surrounding oral insulin was based on its potential to improve patient compliance by replacing injections with oral administration, thus expanding the user base [5][6]. Group 2: Challenges Faced - The development of oral insulin has proven to be extremely challenging due to the instability of insulin in the gastrointestinal tract and the difficulty in achieving stable bioavailability [6]. - Tianmai faced delays in obtaining necessary approvals for injectable insulin, and the introduction of centralized procurement in China significantly altered the market dynamics, leading to price reductions and increased competition from larger players [6][7]. Group 3: Recent Developments and Strategic Shift - In 2023, Oramed's failure to meet primary and secondary endpoints in Phase III trials for ORM-0801 posed a significant setback for the oral insulin narrative, leading to diminished investor confidence and uncertainty regarding future funding [9]. - Following these developments, China Resources Pharmaceutical opted to divest its stake in Tianmai, indicating a strategic pivot towards more certain and commercially viable products, such as a partnership with Borui Pharmaceutical for BGM0504 [10]. Group 4: Market Context and Future Outlook - The divestment reflects a broader trend in the pharmaceutical industry where large companies are increasingly focused on maximizing returns on capital and minimizing exposure to high-risk projects [11]. - Despite the withdrawal from oral insulin, the article suggests that there may still be potential for value in Tianmai, as the company explores new avenues such as GLP-1 analogs, although the competitive landscape has become significantly more challenging [10][11].

Group 1 - The company is enhancing its business capabilities in diabetes GLP-1, weight loss drug semaglutide, and rare cancer diseases, indicating potential competitiveness against global pharmaceutical giants for overseas market expansion [1] - The company is actively pursuing international registration and certification for its proprietary products, aiming to address unmet clinical needs with innovative offerings, thereby improving the accessibility and affordability of vaccines and therapeutic products [1] - The company encourages stakeholders to monitor its regular reports for updates on overseas sales revenue [1]

Core Viewpoint - The resignation of Chen Yingge, the Secretary of the Board of Baili Tianheng, is attributed to personal reasons, effective immediately upon the announcement, with Zhang Suya temporarily assuming the role until a new secretary is appointed [1][3]. Group 1: Resignation Details - Chen Yingge submitted his resignation and will no longer hold any position within the company [1]. - The company expressed gratitude for Chen's contributions in governance, information disclosure, and investor relations during his tenure [3]. Group 2: Background Information - Chen Yingge, born in 1991, holds a Master's degree in Drug Design from University College London (UCL) and is qualified as a Secretary of the Board for the Sci-Tech Innovation Board of the Shanghai Stock Exchange [3]. - Prior to joining Baili Tianheng in April 2024, Chen held various positions at Junshi Biosciences from April 2017 to April 2024, including Secretary of the Board and authorized representative [3]. - In 2024, Chen's salary at Baili Tianheng was reported to be 1.0475 million yuan [3].

2026年1月18日公告显示，公司已收回一笔账龄超5年的应收账款609.94万元，债权债务关系结清，预计 对2026年度财务状况产生积极影响。 公司状况 2026年1月5日，公司临时股东会审议通过增加经营范围并修订公司章程的议案，可能涉及业务拓展。 股票近期走势 经济观察网根据公开信息，江苏硕世生物科技股份有限公司(股票代码：688399)近期有以下事件值得关 注，这些事件可能对公司经营或市场表现产生影响。 业绩经营情况 2026年1月30日，公司发布业绩预告，预计2025年度归属于母公司所有者的净利润为-2,940万元至-4,400 万元，较上年同期亏损扩大，主要受行业竞争加剧、医疗集采及增值税税率调整等因素影响。正式年报 尚未发布，需关注后续披露。 财务状况 2026年2月11日，股价报68.75元/股，当日下跌2.01%，主力资金净流出479.48万元，成交额3901.39万 元。融资余额方面，截至2026年2月2日，公司融资余额为3.92亿元，占流通市值比例较高，处于近一年 90%分位水平。 未来发展 2025年12月实际控制人续签《一致行动协议》，以及公司产品被列入世界卫生组织应急使用清单等，可 能 ...

安沐奇塔单抗在关键注册性III期临床研究中，所有主要疗效终点和关键次要疗效终点均成功达到，尤其 在皮损完全清除的PASI100指标上显示出显著的疗效优势。 此外，安沐奇塔单抗的抗药抗体（ADA）发生率仅为0.7%，显示出较好的安全性和耐受性。该药物提 供每4周或每8周一次的灵活给药选择，有望减少患者的用药频率，降低长期治疗的时间成本与心理压 力。 近日，三生国健发布公告称，公司自主研发的抗IL-17A人源化单克隆抗体安沐奇塔单抗注射液（商品 名：益赛拓 ）的新药上市申请已获得国家药品监督管理局批准，用于治疗适合系统治疗或光疗的中度 至重度斑块状银屑病成人患者。 此次安沐奇塔单抗获批上市将丰富公司的自免商业化产品管线，提升市场竞争力，对公司的经营发展产 生积极作用。公告指出，此次获批不会对公司当前财务状况和经营成果产生重大影响，但对未来业绩提 升有一定积极作用。 ...

Core Viewpoint - The approval of the anti-IL-17A monoclonal antibody, Anmucita, by Sanofi is a significant milestone for the domestic innovative drug industry, enhancing the competitive landscape in the treatment of autoimmune diseases like psoriasis [1] Group 1: Market Trends and Competitive Landscape - The market position of anti-IL-17 treatments is gradually increasing, with Novartis's Cosentyx projected to achieve sales of $6.668 billion by 2025, reflecting a 9% year-on-year growth [1] - As imported products approach patent expiration, sales growth is slowing, leading to increased focus on domestic players, including Sanofi's Anmucita, Hengrui's innovative drug, and others [1] - The domestic autoimmune drug market is expected to reach $4.6 billion by 2024, with a compound annual growth rate (CAGR) of 15.9% from 2020 to 2024, and projected to grow to $35.2 billion by 2034 [7] Group 2: Clinical Advantages of Anmucita - Anmucita demonstrates a significantly lower immunogenicity rate of only 0.7%, with no patients developing neutralizing antibodies, which enhances its clinical efficacy [4] - The drug shows rapid onset of action, with symptom relief occurring within two weeks of the first dose, and maintains high response rates (over 92%) for PASI75 and PASI90 at 52 weeks [4] - Anmucita offers a long dosing interval of Q8W (every 8 weeks), improving patient compliance while maintaining stable efficacy [4] Group 3: Company Strengths and Innovation - Sanofi's confidence stems from over 20 years of experience in target discovery, early development, and a comprehensive innovation system, positioning it ahead of many local biotech firms [5] - The company has established a robust antibody drug development platform and talent pool, enabling it to efficiently navigate the drug approval process and commercialize products [8] - Sanofi's extensive experience in the autoimmune sector allows it to leverage its commercial capabilities and channel coverage for seamless product launch and market penetration [8]

经济观察网 维立志博-B获纳入恒生综合指数并有望成为港股通标的，核心产品研发获FDA快速通道资 格，基石投资者解禁及港股通纳入预期引关注。 基石投资者解禁：公司于2026年1月25日迎来基石投资者解禁，涉及9名基石投资者（如正新谷资本、腾 讯等），认购总额约5.42亿港元。解禁后市场承接力表现可能成为场外资金的参考指标。 港股通纳入预期：在2025年检讨周期内，公司日平均市值为94.62亿港元，超过92.47亿港元的门槛，符 合港股通纳入条件，最终结果预计于2026年3月确认。 以上内容基于公开资料整理，不构成投资建议。 LBL-024（PD-L1/4-1BB双特异性抗体）：2026年1月14日获美国FDA授予快速通道资格，用于治疗肺外 神经内分泌癌；此前已在非小细胞肺癌、小细胞肺癌等适应症的II期或注册性临床试验中展示潜力。 LBL-034（GPRC5D/CD3双特异性抗体）：2026年1月27日获美国FDA快速通道资格，用于治疗复发/难 治性多发性骨髓瘤，凸显公司TCE平台的技术优势。 资金动向 股票近期走势 根据恒生指数公司2026年2月13日公布的季度检讨结果，维立志博-B被纳入恒生综合指数。该变动计 ...

Core Insights - The article discusses the unpredictable nature of the market and the importance of adaptability for entrepreneurs, especially during economic fluctuations [4][6]. - It emphasizes the significance of long-term strategies over short-term gains in entrepreneurship, highlighting the need for resilience and careful decision-making [8][11]. Financing and Market Conditions - The article reflects on the current state of financing, indicating a warming market compared to previous years, with a focus on how entrepreneurs navigated through capital winters [6][10]. - It mentions that many entrepreneurs faced significant challenges during the capital winter, including budget overruns and delays in project delivery, which led to critical adjustments in their business strategies [9][10]. Entrepreneurial Experiences - Entrepreneurs shared their experiences of overcoming financial difficulties, including instances where they had to halt projects due to cash flow issues and the importance of maintaining team morale during tough times [10][11]. - The article highlights the shift in focus for some companies from ambitious expansion plans to more sustainable, focused product development in response to market conditions [17][18]. Industry Trends and Future Outlook - The article notes that the synthetic biology and AI sectors are gaining traction, with significant potential for growth as they align with national policies and market demands [12][21]. - It discusses the increasing interest from investors in sectors like biotechnology and industrial automation, indicating a shift in funding dynamics and a growing recognition of the long-term value of these industries [52][53]. Strategic Partnerships and Collaborations - The importance of strategic partnerships is emphasized, with examples of companies successfully collaborating with larger firms to enhance their operational capabilities and market reach [10][27]. - The article also mentions how companies are leveraging government support and resources to navigate challenging market conditions and secure funding [52][55].

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Kintor Pharmaceutical-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostic Technology, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for this project will not exceed RMB 370 million, aimed at constructing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

Group 1 - The company has decided to terminate the issuance of A-shares to specific investors for the year 2025 and has withdrawn the application documents [1] - On February 11, 2026, the company and its sponsor, Guohai Securities Co., Ltd., submitted applications to the Shanghai Stock Exchange to withdraw the application documents and the sponsorship work [1] - The Shanghai Stock Exchange has officially decided to terminate the review of the company's application for the issuance of shares to specific investors [2]